1 Computational Health Informatics Program, Boston Children's Hospital , Boston, Massachusetts.
2 Department of Information Management, Chang Gung University , Taoyuan, Taiwan .
Vector Borne Zoonotic Dis. 2017 Feb;17(2):116-122. doi: 10.1089/vbz.2016.1991. Epub 2016 Nov 17.
A Lyme disease (LD) diagnosis can be far from straightforward, particularly if erythema migrans does not develop or is not noticed. Extended courses of antibiotics for LD are not recommended, but their use is increasing. We sought to elucidate the patient patterns toward a diagnosis of LD, hypothesizing that a subset of patients ultimately receiving extended courses antibiotics may be symptomatic for an extended period before the first LD diagnosis.
Claims submitted to a nationwide U.S. health insurance plan in 14 high-prevalence states were grouped into standardized diagnostic categories. The patterns of diagnostic categories over time were compared between patients evaluated for LD and given standard antibiotic therapy (PLDSA) and patients evaluated for LD and given extended antibiotic therapy (PLDEA) in 2011-2012.
The incidence of PLDSA was 40.45 (N = 3207) and that of PLDEA was 7.57 (N = 600) per 100,000 insured over 2011-2012. 50.3% of PLDEA were diagnosed in the nonsummer months. Seven diagnostic categories were associated with PLDEA. From 180 days before the first LD diagnosis, the risks of having claims associated with back problems (odds ratio [OR], 2.1; confidence interval [95% CI], 1.4-2.9; p < 0.001) and connective tissue disease (OR, 1.6; 95% CI, 1.1-2.3; p < 0.01) complaints were higher among PLDEA. From 90 days before the diagnosis, malaise and fatigue (OR, 1.7; 95% CI, 1.1-2.6; p < 0.05), other nervous system disorders (OR, 2.0; 95% CI, 1.3-3.1; p < 0.01), and nontraumatic joint disorder (OR, 1.4; 95% CI, 1.0-2.0; p < 0.05) were more likely found among PLDEA than PLDSA. From 30 days before the diagnosis, the risk for mental health (OR 1.6; 95% CI, 1.1-2.0; p < 0.01) and headache (OR 1.5; 95% CI, 1.1-2.0; p < 0.05) among PLDEA was elevated.
Among patients evaluated for LD and ultimately receiving an extended course of antibiotics for LD, 15.8% of them were symptomatic and seeking care for several months before their first LD diagnosis.
莱姆病(LD)的诊断可能非常复杂,尤其是如果游走性红斑没有出现或没有被注意到。不推荐对 LD 进行延长疗程的抗生素治疗,但这种治疗方法的使用正在增加。我们试图阐明 LD 诊断的患者模式,假设最终接受延长疗程抗生素治疗的患者亚组可能在首次 LD 诊断之前有较长时间的症状。
将向美国全国性医疗保险计划提交的索赔按标准化诊断类别进行分组。2011-2012 年,比较了接受 LD 评估和标准抗生素治疗的患者(PLDSA)和接受 LD 评估和延长抗生素治疗的患者(PLDEA)的诊断类别随时间的变化模式。
2011-2012 年,PLDSA 的发病率为每 100,000 名参保人 40.45(N=3207),PLDEA 的发病率为 7.57(N=600)。50.3%的 PLDEA 是在非夏季月份诊断出来的。有 7 种诊断类别与 PLDEA 相关。从首次 LD 诊断前 180 天开始,出现背部问题(比值比 [OR],2.1;95%置信区间 [95%CI],1.4-2.9;p<0.001)和结缔组织疾病(OR,1.6;95%CI,1.1-2.3;p<0.01)的索赔风险更高。从诊断前 90 天开始,不适和疲劳(OR,1.7;95%CI,1.1-2.6;p<0.05)、其他神经系统疾病(OR,2.0;95%CI,1.3-3.1;p<0.01)和非创伤性关节疾病(OR,1.4;95%CI,1.0-2.0;p<0.05)在 PLDEA 中更为常见。从诊断前 30 天开始,PLDEA 患者的心理健康(OR 1.6;95%CI,1.1-2.0;p<0.01)和头痛(OR 1.5;95%CI,1.1-2.0;p<0.05)的风险增加。
在接受 LD 评估并最终接受 LD 延长疗程抗生素治疗的患者中,有 15.8%的患者在首次 LD 诊断前有几个月的症状,并在寻求治疗。